- Home
- ALTO vs ADAP Comparison
ALTO vs ADAP Comparison
Compare ALTO & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTO
- ADAP
- Stock Information
- Founded
- ALTO 2003
- ADAP 2008
- Country
- ALTO United States
- ADAP United Kingdom
- Employees
- ALTO N/A
- ADAP N/A
- Industry
- ALTO Major Chemicals
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- ALTO Industrials
- ADAP Health Care
- Exchange
- ALTO Nasdaq
- ADAP Nasdaq
- Market Cap
- ALTO 90.3M
- ADAP 75.5M
- IPO Year
- ALTO N/A
- ADAP 2015
- Fundamental
- Price
- ALTO $1.25
- ADAP $0.27
- Analyst Decision
- ALTO Strong Buy
- ADAP Buy
- Analyst Count
- ALTO 1
- ADAP 6
- Target Price
- ALTO $5.50
- ADAP $1.35
- AVG Volume (30 Days)
- ALTO 307.0K
- ADAP 644.7K
- Earning Date
- ALTO 08-05-2025
- ADAP 08-11-2025
- Dividend Yield
- ALTO N/A
- ADAP N/A
- EPS Growth
- ALTO N/A
- ADAP N/A
- EPS
- ALTO N/A
- ADAP N/A
- Revenue
- ALTO $951,169,000.00
- ADAP $179,639,000.00
- Revenue This Year
- ALTO N/A
- ADAP N/A
- Revenue Next Year
- ALTO $7.68
- ADAP $35.48
- P/E Ratio
- ALTO N/A
- ADAP N/A
- Revenue Growth
- ALTO N/A
- ADAP 878.53
- 52 Week Low
- ALTO $0.76
- ADAP $0.20
- 52 Week High
- ALTO $2.05
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- ALTO 69.00
- ADAP 56.59
- Support Level
- ALTO $1.22
- ADAP $0.23
- Resistance Level
- ALTO $1.28
- ADAP $0.28
- Average True Range (ATR)
- ALTO 0.07
- ADAP 0.02
- MACD
- ALTO 0.01
- ADAP 0.00
- Stochastic Oscillator
- ALTO 95.73
- ADAP 87.96
About ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include major food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, Western production, and Others.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.